Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
- Piper Sandler 32nd Annual
Virtual Healthcare Conference Evercore ISI3rd Annual HealthCONx Virtual Conferenceon Thursday, December 3, 2020at 12:10pm ET
A webcast of the live Evercore presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. A replay of the pre-recorded Piper fireside chat is currently available on the Company’s website. The webcasts will be archived on the Company’s website for 90 days following the presentation.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Source: Protara Therapeutics